<DOC>
	<DOCNO>NCT01806272</DOCNO>
	<brief_summary>This open , randomized phase II trial compare effectiveness safety local use rhGM-CSF Compound Vitamin B12 Compound Vitamin B12 solution alone treat oral mucositis primary nasopharyngeal cancer . The main end point incidence grade II less oral mucositis end treatment.The hypothesis study local use rhGM-CSF Compound Vitamin B12 decrease incidence grade III oral mucositis end treatment compare local use Compound Vitamin B12 alone .</brief_summary>
	<brief_title>Recombinant Human Granulocyte Macrophage Colony Stimulating Factor ( rhGM-CSF ) Treating Oral Mucositis</brief_title>
	<detailed_description>Inclusion Criteria : 1 . Grade II oral mucositis induce chemoradiotherapy patient primary nasopharyngeal carcinoma . 2 . Receiving 68-72 Gray radiation dose . 3 . Age 18 65 year . 4 . KPS≥70 . 5 . Patient give his/her write consent specific procedure protocol . Exclusion Criteria : 1 . Severe uncontrolled infection . 2 . Pregnant breast-feeding female . 3 . Allergy medicine . 4 . Diarrhea . Outcome measure : 1 . Grade oral mucositis : NCI Common Terminology Criteria Adverse Events v3.0 , NCI CTCAE v3.0 2 . Pain : WHO , Numerical Rating Scale ( NRS ) 3 . Tumor response chemoradiotherapy : Response Evaluation Criteria Solid Tumors , RECIST1.1</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Molgramostim</mesh_term>
	<criteria>1 . Grade II oral mucositis induce chemoradiotherapy patient primary nasopharyngeal carcinoma . 2 . Receiving 6872 Gray radiation dose . 3 . Age 18 65 year . 4 . KPS≥70 . 5 . Patient give his/her write consent specific procedure protocol . 1 . Severe uncontrolled infection . 2 . Pregnant breastfeeding female . 3 . Allergy medicine . 4 . Diarrhea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>rhGM-CSF</keyword>
	<keyword>Oral Mucositis</keyword>
	<keyword>Primary Nasopharyngeal Cancers</keyword>
	<keyword>Chemoradiotherapy</keyword>
</DOC>